The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Implications of a higher-for-longer rate regime
General Catalyst CEO Hemant Taneja on mission-driven investing, health assurance, and AI’s transformation advantage
Why most Americans aren’t saving enough for retirement
The IPO market’s soft opening
Tech companies are investing in growth
Emerging market equities poised to overtake developed market equities
How companies, private equity firms, and institutional investors are navigating the global economy
A conversation with Renaissance Technologies CEO Peter Brown
The Fed is likely finished hiking rates as the US avoids recession
The economic potential of closing gender and racial gaps
The music industry’s turning point
BlackRock’s Rick Rieder on his career, the markets, and investing in the current environment
Corporate credit concerns
Germany: a country at the crossroads
Why the U.K.’s high inflation has global implications
Man Group CEO Luke Ellis on hedge funds, quantitative strategies and lessons in leadership
What’s next for China’s economy?
Generative AI: hype, or truly transformative?
Why 'everything aligns' for Japanese stocks
Why global equities are poised for “fat and flat” returns
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
TED Radio Hour
FT Alphachat
Freakonomics Radio
Stephanomics
Odd Lots